Talaris Therapeutics Inc. (TALS)
NASDAQ: TALS
· Real-Time Price · USD
2.72
-0.02 (-0.73%)
At close: Oct 19, 2023, 10:00 PM
Talaris Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -25.97M | -26.23M | -40.22M | -24.44M | -21.97M | -8.93M | -16.5M | -24.08M | -19.82M | -19.82M | -18.41M | -18.41M | -14.39M | -13.06M | -11.06M | -9.01M |
Interest Income | n/a | n/a | -1.76M | n/a | n/a | n/a | 1.76M | n/a | 300.00 | 200.00 | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -23.09M | -22.97M | -28.96M | -20.18M | -17.49M | -7.01M | -14.74M | -22.5M | -18.53M | -19.01M | -18.1M | -18.26M | -14.24M | -12.94M | -11.35M | -9.3M |
Net Income | -23.09M | -22.97M | -28.96M | -20.18M | -17.49M | -7.01M | -14.74M | -20.92M | -14.99M | -18.2M | -18.1M | -18.26M | -14.24M | -12.94M | -11.35M | -9.3M |
Selling & General & Admin | 6.34M | 5.97M | 1.43M | 5.11M | 6.24M | 9.11M | 6.03M | 6.18M | 5.18M | 4.84M | 5.23M | 4.22M | 3.8M | 3.87M | 3.49M | 2.54M |
Research & Development | 19.63M | 20.26M | 49.22M | 19.33M | 15.73M | 267K | 4.09M | 13.41M | 14.64M | 14.98M | 13.19M | 14.2M | 10.59M | 9.18M | 7.57M | 6.47M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 89K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 25.97M | 26.23M | 50.64M | 24.44M | 21.97M | 9.47M | 10.11M | 19.6M | 19.82M | 19.82M | 18.41M | 18.41M | 14.39M | 13.06M | 11.06M | 9.01M |
Interest Expense | n/a | n/a | -3.68M | n/a | n/a | 1.92M | 1.76M | n/a | 1.77M | 812K | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | n/a | 50.64M | n/a | n/a | 9.47M | 10.11M | 19.6M | 19.82M | 19.82M | 18.41M | 18.41M | 14.39M | 13.06M | 11.06M | 9.01M |
Income Tax Expense | n/a | n/a | -3.04M | n/a | n/a | n/a | n/a | -1.58M | -3.54M | -812K | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 25.75M | 25.69M | 25.35M | 25.77M | 25.72M | 4.27M | 4.22M | 4.18M | 4.15M | 4.14M | 41.09M | 40.98M | 40.93M | 40.67M | 27.37M | 41.24M |
Shares Outstanding (Diluted) | 25.75M | 25.69M | 25.35M | 25.77M | 25.72M | 4.27M | 4.22M | 4.18M | 4.15M | 4.14M | 41.09M | 40.98M | 40.93M | 40.67M | 27.37M | 41.24M |
EPS (Basic) | -0.9 | -0.89 | 7.24 | -0.78 | -0.68 | -1.64 | -3.49 | -5 | -3.61 | -4.4 | -0.44 | -0.45 | -0.35 | -0.32 | -0.41 | -0.23 |
EPS (Diluted) | -0.9 | -0.89 | 7.24 | -0.78 | -0.68 | -1.64 | -3.49 | -5 | -3.61 | -4.4 | -0.44 | -0.45 | -0.35 | -0.32 | -0.41 | -0.23 |
EBITDA | -25.97M | -26.23M | -47.09M | -24.44M | -21.97M | -8.93M | -16.5M | -14.48M | 1.74M | -19.25M | -17.86M | -17.93M | -14.2M | -12.89M | -10.92M | -8.87M |
EBIT | n/a | n/a | 18.07M | n/a | n/a | -5.1M | -12.97M | -24.08M | -16.76M | -18.2M | -18.41M | -18.41M | -14.39M | -13.06M | -11.06M | -9.01M |
Depreciation & Amortization | n/a | n/a | -9.82M | n/a | n/a | -39.59K | 261K | 9.6M | 553K | 570K | 551K | 488K | 188K | 167K | 133K | 135K |